Actively Recruiting
Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma
Led by National Taiwan University Hospital · Updated on 2025-08-13
90
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how glaucoma and the medications used to treat it affect the thickness of the corneal and limbal epithelium, which reflects the health of limbal stem cells important for eye surface protection. This observational study focuses on glaucoma patients with various treatment durations and aims to understand the link between tear fluid proteins and limbal function. The goal is to provide insights for early detection and future drug development to protect limbal stem cells. Participants include healthy controls without glaucoma, newly diagnosed glaucoma patients using medication for less than 3 months, glaucoma patients on long-term medication for over a year, and patients with treatment in only one eye. The study will measure corneal and limbal epithelial thickness and analyze tear fluid proteomics at enrollment and again after 6 months for newly diagnosed patients. During the study, participants will undergo eye thickness measurements and tear sample collection at specified times. Researchers will review changes in limbal epithelial thickness primarily, along with corneal thickness and tear protein profiles, to evaluate limbal function. The study starts in July 2025 and is expected to continue until December 2026, providing valuable data on glaucoma medication effects and ocular surface health.
CONDITIONS
Brief Title
Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Healthy controls without diagnosis of glaucoma or ocular hypertension
- Newly diagnosed glaucoma or ocular hypertension patients using antiglaucoma medication for less than 3 months
- Glaucoma or ocular hypertension patients on intraocular pressure-lowering medication for more than 1 year
- Patients with unilateral glaucoma or ocular hypertension treated in only one eye
You will not qualify if you...
- History of severe ocular trauma, chemical burns, corneal ulcers, Stevens-Johnson syndrome with eye involvement, or ocular graft-versus-host disease
- History of corneal or conjunctival surgery, trabeculectomy, or glaucoma drainage device implantation
- Presence of ocular surface irregularity or limbal dysfunction from causes other than glaucoma or dry eye disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Enrollment day
Participants undergo assessments including limbal epithelial thickness and proteomic analysis of tear samples upon enrollment.
1 visit (in-person)
Duration - 6 months
Participants, especially those newly diagnosed, are monitored with repeat assessments at 6 months after enrollment to observe changes over time.
1 follow-up visit at 6 months
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital Hsinchu Branch
Hsinchu, Taiwan
Actively Recruiting
Research Team
W
Wei-Lun Huang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here